Alisha Braun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alisha Braun has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Larisa Bobrovskaya
Health and Biomedical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, Australia
4 shared publications Akihiro Yamanaka
Chinese Institute for Brain Research Beijing China
1 shared publicationJessica Racz
Health and Biomedical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia
1 shared publicationJim Manavis
Discipline of Anatomy and Pathology, Adelaide Medical School University of Adelaide Adelaide South Australia Australia
1 shared publicationLarisa Bobrovskaya
Health and Biomedical Innovation, Clinical and Health Sciences University of South Australia Adelaide South Australia Australia
1 shared publication- Paul Hamill Anderson
Clinical and Health Sciences, University of South Australia, Adelaide, Australia
1 shared publication
Latest Publications
- Open Access
- 9 July 2026
- Published by Elsevier in Neurochemistry International
- Vol. 199, 106222
Unilateral striatal 6-hydroxydopamine lesion in female mice induces nigrostriatal degeneration with motor, gastrointestinal and skeletal dysfunction.
- 9 July 2026
- Published by Elsevier in Neurochemistry International
- Vol. 199, 106222
Open AccessUnilateral striatal 6-hydroxydopamine lesion in female mice induces nigrostriatal degeneration with motor, gastrointestinal and skeletal dysfunction.
- Open Access
- 20 June 2026
- Published by Elsevier in Brain Research
- Vol. 1888, 150437
Progressive orexin A positive neuron loss in the 6-OHDA mouse model of Parkinson’s disease: a pilot study with validation of an orexin A immunohistochemistry protocol for paraffin-embedded tissue
- 20 June 2026
- Published by Elsevier in Brain Research
- Vol. 1888, 150437
Open AccessProgressive orexin A positive neuron loss in the 6-OHDA mouse model of Parkinson’s disease: a pilot study with validation of an orexin A immunohistochemistry protocol for paraffin-embedded tissue
- Open Access
- 3 March 2026
- Published by Springer Nature in Current Behavioral Neuroscience Reports
- Vol. 13 (1) , 4
Non-motor Symptom Replication in Neurotoxic Mouse Models of Parkinson’s Disease: A Review and Guide
Purpose of review: This review discusses non-motor symptom replication in neurotoxic mouse models of Parkinson’s disease (PD). Non-motor symptoms can begin years prior to the onset of motor symptoms, with the cause of non-motor symptoms remaining widely unknown. This highlights the need for researchers to investigate non-motor symptom pathology, with the aim of earlier diagnosis and identifying potential early and alternative treatment options. Recent findings: Neurotoxic models are the most common Parkinson’s disease models in mice, as they are quick to induce, reproducible, cost-effective and replicate dopaminergic neuron loss and symptoms. The non-motor symptoms of Parkinson’s disease included in this review are olfactory dysfunction, anxiety, depression, sleep and circadian rhythm disorders, cognitive impairments and gastrointestinal dysfunction. We have reviewed the most commonly used behavioural tests for each non-motor symptom in neurotoxic models in mice, and have provided some recommendations and highlighted their limitations. Summary: This review provides a comprehensive review of studies in one place for the researcher to make quick and easy decisions on what neurotoxic model to use and what test to use to replicate the required non-motor symptom based on the aims of the researcher. Through the replication of non-motor symptoms and modelling PD in mice, researchers can help uncover the pathogenesis and potential treatments for non-motor symptoms in PD. We hope this review will be useful for the beginners and experienced researchers who wish to embark on behavioural tests in neurotoxin mouse models of Parkinson’s disease to investigate the molecular mechanisms and possible treatments.
- 3 March 2026
- Published by Springer Nature in Current Behavioral Neuroscience Reports
- Vol. 13 (1) , 4
Open AccessNon-motor Symptom Replication in Neurotoxic Mouse Models of Parkinson’s Disease: A Review and Guide
Purpose of review: This review discusses non-motor symptom replication in neurotoxic mouse models of Parkinson’s disease (PD). Non-motor symptoms can begin years prior to the onset of motor symptoms, with the cause of non-motor symptoms remaining widely unknown. This highlights the need for researchers to investigate non-motor symptom pathology, with the aim of earlier diagnosis and identifying potential early and alternative treatment options. Recent findings: Neurotoxic models are the most common Parkinson’s disease models in mice, as they are quick to induce, reproducible, cost-effective and replicate dopaminergic neuron loss and symptoms. The non-motor symptoms of Parkinson’s disease included in this review are olfactory dysfunction, anxiety, depression, sleep and circadian rhythm disorders, cognitive impairments and gastrointestinal dysfunction. We have reviewed the most commonly used behavioural tests for each non-motor symptom in neurotoxic models in mice, and have provided some recommendations and highlighted their limitations. Summary: This review provides a comprehensive review of studies in one place for the researcher to make quick and easy decisions on what neurotoxic model to use and what test to use to replicate the required non-motor symptom based on the aims of the researcher. Through the replication of non-motor symptoms and modelling PD in mice, researchers can help uncover the pathogenesis and potential treatments for non-motor symptoms in PD. We hope this review will be useful for the beginners and experienced researchers who wish to embark on behavioural tests in neurotoxin mouse models of Parkinson’s disease to investigate the molecular mechanisms and possible treatments.
- Open Access
- 22 September 2025
- Published by Elsevier in Neurochemistry International
- Vol. 190, 106054
Further characterisation of the intrastriatal 6-OHDA Parkinson's disease model with non-motor symptom replication and widespread catecholamine dysfunction in male mice
- 22 September 2025
- Published by Elsevier in Neurochemistry International
- Vol. 190, 106054
Open AccessFurther characterisation of the intrastriatal 6-OHDA Parkinson's disease model with non-motor symptom replication and widespread catecholamine dysfunction in male mice
- Open Access
- 23 March 2024
- Published by Wiley in Journal of Neuroscience Research
- Vol. 102 (3) , e25322
The role of orexin in Parkinson's disease
Emerging evidence has implicated the orexin system in non‐motor pathogenesis of Parkinson's disease. It has also been suggested the orexin system is involved in the modulation of motor control, further implicating the orexin system in Parkinson's disease. Parkinson's disease is the second most common neurodegenerative disease with millions of people suffering worldwide with motor and non‐motor symptoms, significantly affecting their quality of life. Treatments are based solely on symptomatic management and no cure currently exists. The orexin system has the potential to be a treatment target in Parkinson's disease, particularly in the non‐motor stage. In this review, the most current evidence on the orexin system in Parkinson's disease and its potential role in motor and non‐motor symptoms of the disease is summarized. This review begins with a brief overview of Parkinson's disease, animal models of the disease, and the orexin system. This leads into discussion of the possible roles of orexin neurons in Parkinson's disease and levels of orexin in the cerebral spinal fluid and plasma in Parkinson's disease and animal models of the disease. The role of orexin is then discussed in relation to symptoms of the disease including motor control, sleep, cognitive impairment, psychological behaviors, and the gastrointestinal system. The neuroprotective effects of orexin are also summarized in preclinical models of the disease.
- 23 March 2024
- Published by Wiley in Journal of Neuroscience Research
- Vol. 102 (3) , e25322
Open AccessThe role of orexin in Parkinson's disease
Emerging evidence has implicated the orexin system in non‐motor pathogenesis of Parkinson's disease. It has also been suggested the orexin system is involved in the modulation of motor control, further implicating the orexin system in Parkinson's disease. Parkinson's disease is the second most common neurodegenerative disease with millions of people suffering worldwide with motor and non‐motor symptoms, significantly affecting their quality of life. Treatments are based solely on symptomatic management and no cure currently exists. The orexin system has the potential to be a treatment target in Parkinson's disease, particularly in the non‐motor stage. In this review, the most current evidence on the orexin system in Parkinson's disease and its potential role in motor and non‐motor symptoms of the disease is summarized. This review begins with a brief overview of Parkinson's disease, animal models of the disease, and the orexin system. This leads into discussion of the possible roles of orexin neurons in Parkinson's disease and levels of orexin in the cerebral spinal fluid and plasma in Parkinson's disease and animal models of the disease. The role of orexin is then discussed in relation to symptoms of the disease including motor control, sleep, cognitive impairment, psychological behaviors, and the gastrointestinal system. The neuroprotective effects of orexin are also summarized in preclinical models of the disease.